ECGvision©
AI-Driven Cardiovascular Insights.
Yale start-up making cardiovascular diagnostics more accessible.
ECGvision-ATTR© is an FDA Breakthrough Device
ECGvision-ATTR© diagnoses Transthyretin Cardiomyopathy from Photos of ECGs. The first-of-its-kind technology received FDA Breakthrough Device Designation in February 2024
Ensight-AI, Inc. is accelerating the development of AI to detect undiagnosed cardiovascular diseases directly from photos of ECGs.
The ECGvision© suite has been developed at Yale School of Medicine’s Cardiovascular Data Science (CarDS) Lab and is designed to reduce disparities in clinical diagnosis for several cardiovascular disorders.